Whitney Ijem
Stock Analyst at Canaccord Genuity
(1.95)
# 2,804
Out of 4,814 analysts
98
Total ratings
32.14%
Success rate
-8.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERV Verve Therapeutics | Maintains: Buy | $32 → $39 | $4.61 | +746.91% | 5 | Apr 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $81 → $92 | $61.65 | +49.23% | 7 | Apr 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $385 → $390 | $234.75 | +66.13% | 8 | Mar 21, 2025 | |
| RGLS Regulus Therapeutics | Maintains: Buy | $28 | $2.04 | +1,272.55% | 5 | Mar 17, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 | $0.39 | +2,201.20% | 2 | Mar 17, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $6 | $0.45 | +1,233.33% | 6 | Mar 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $74 → $68 | $10.51 | +547.00% | 5 | Mar 10, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 → $36 | $6.33 | +468.72% | 6 | Mar 3, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $39 | $24.24 | +60.89% | 2 | Feb 26, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 → $136 | $35.64 | +281.59% | 8 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $408 → $424 | $489.10 | -13.31% | 8 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 | $7.27 | +1,138.82% | 5 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.25 | +540.00% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 | $0.31 | +4,040.13% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $53.79 | +178.86% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $59.12 | +42.08% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $104.53 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $5.06 | +4,647.77% | 4 | Jul 23, 2019 |
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $4.61
Upside: +746.91%
Rhythm Pharmaceuticals
Apr 8, 2025
Maintains: Buy
Price Target: $81 → $92
Current: $61.65
Upside: +49.23%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $385 → $390
Current: $234.75
Upside: +66.13%
Regulus Therapeutics
Mar 17, 2025
Maintains: Buy
Price Target: $28
Current: $2.04
Upside: +1,272.55%
Generation Bio Co.
Mar 17, 2025
Maintains: Buy
Price Target: $9
Current: $0.39
Upside: +2,201.20%
Tenaya Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $0.45
Upside: +1,233.33%
Arcturus Therapeutics Holdings
Mar 10, 2025
Maintains: Buy
Price Target: $74 → $68
Current: $10.51
Upside: +547.00%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Buy
Price Target: $39 → $36
Current: $6.33
Upside: +468.72%
Palvella Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $39
Current: $24.24
Upside: +60.89%
Ultragenyx Pharmaceutical
Feb 18, 2025
Maintains: Buy
Price Target: $121 → $136
Current: $35.64
Upside: +281.59%
Feb 12, 2025
Upgrades: Hold
Price Target: $408 → $424
Current: $489.10
Upside: -13.31%
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $7.27
Upside: +1,138.82%
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.25
Upside: +540.00%
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.31
Upside: +4,040.13%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $53.79
Upside: +178.86%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $59.12
Upside: +42.08%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $104.53
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $5.06
Upside: +4,647.77%